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Systemic lupus erythematosus (SLE) develops in relation to many environmental factors. In our opinion, it is more important to
investigate the eﬀect of melatonin on the environmental- related SLE. In the present study, 0.5ml pristane were used to induce
SLE in female BALB/c mice. Melatonin (0.01, 0.1, 1.0mg/kg) was orally administered immediately after pristane-injection for 24
weeks. IgM anti ssDNA and histone antibodies were detected after 0, 1, 2, 4, 8 weeks pristane injection. The levels of IL-2, IL-6 and
IL-13were detected after 24 weeks. Renal lesions were also observed. Theresultsshowed that melatonin antagonized theincreasing
levels of IgM anti ssDNA and histone autoantibodies. Melatonin could also decrease the IL-6 and IL-13 production and increase
the IL-2 production. Besides, melatonin could lessen the renal lesions caused by pristane. These results suggested that melatonin
has a beneﬁcial eﬀect on pristane-induced lupus through regulating the cytokines disturbances.
1.Introduction
Systemic lupus erythematosus (SLE or Lupus) is an autoim-
mune disease that can attack the body’s normal tissue and
cells,resultingininﬂammationandtissuedamage[1,2].SLE
occurs at any age and in any gender. However, women are
more likely to have SLE than men [3, 4]. Besides, disturbance
in the cytokine network has also been reported in SLE [5],
including IL-1, IL-2, IL-6, IL-13, and IFN-α. These cytokines
have close relations to the development of SLE such as
autoantibodies production and immune-complex nephritis.
But there are some contradictory results about the changes
of some cytokines in diﬀerent reports.
Inrecentyears,moreandmoreattentionhasbeenpaidto
environmental factors that may be implicated in the patho-
genesis of SLE [6, 7]. Autoimmune diseases are becoming
increasingly common in industrialized countries, and these
diseases can be inﬂuenced by environmental factors [8].
Pristane is a likely candidate as an environmental trigger of
SLE in susceptible population. Animal experiments showed
that pristane could induce lupus-like autoimmune disease
symptoms in a strain of mice (BALB/c), such as high levels
of autoantibodies and immune-complex glomerulonephritis
[9, 10]. Some epidemiological investigations also proved that
all of the persons with pristane in their blood had distinct
autoimmune diseases or symptoms of autoimmune disease
[11].Inaddition,pristanefoundinmineraloil,sharkoil,and
many foods seems to be a possible environmental exposure
that may trigger SLE. So it might be more appropriate to
research environmental factors involved in SLE by using
pristane-induced SLE-like murine model.
Melatonin is synthesized and secreted mainly by the
pineal gland that can make speciﬁc receptors in and out
of the central nervous system. Melatonin not only can
directly aﬀect inﬂammation and immune cells, but also has
indirect inﬂuences on it through thalamencephalon [12].
More importantly, melatonin is regarded as an important
active substance in the neuro-immune-endocrine system
[13]. It is able to regulate the imbalance of cytokine
network in some autoimmune diseases such as rheumatoid2 Mediators of Inﬂammation
arthritis and adjuvant arthritis [14, 15]. Some experiments
investigated its eﬀects on MRL-lpr/lpr mice and showed
that melatonin was beneﬁcial for spontaneous SLE in
female mice [16]. Since environment is an important
factor in SLE in modern society, we were more interested
in the eﬀects of melatonin on the environmental-related
SLE.
To investigate the role of melatonin in SLE, especially
in the environmental-related lupus, pristane-induced mice
were used. The eﬀects of melatonin on the cytokine distur-
bances and the following changes in pristane-induced SLE
model were also determined.
2.MaterialsandMethods
2.1. Animals. Sixty female BALB/c mice aged two months
(17 ± 2g) were supplied by the Experimental Animal Center
of Anhui Medical University. All experimental protocols
described in this study were approved by the Ethics Review
Committee for Animal Experimentation of Institute of
Clinical Pharmacology, Anhui Medical University.
2.2. Materials. Melatonin was purchased from Sigma. Pris-
tane, heat-denatured calf thymus DNA (ssDNA), total
calf thymus histone (histone), concanavalin A (ConA),
and lipopolysaccharides (LPS) were also from Sigma.
Biotin-conjugated rabbit-anti-mouse IgM antibodies and
horseradish peroxidase-labeled avidin were purchased from
SABC. Mouse interleukin-2 ELISA kits and interleukin-6
ELISA kits were purchased from ADL. Mouse interleukin-13
ELISA kits were purchased from BIOO.
2.3. Experimental Protocols. Sixty female BALB/c mice were
randomly divided into six groups: normal control group,
model group, prednisone-treatment group which served as
positive control group, and melatonin (0.01, 0.1, 1.0mg/kg)
treatment groups including melatonin group one (MT1),
melatonin group two (MT2), and melatonin group three
( M T 3 ) .T h em i c ei nn o r m a lc o n t r o lg r o u pw e r eg i v e na n
intraperitoneal injection of 0.5ml normal saline (NS), and
the other groups were given an intraperitoneal injection of
0.5mlpristane.Themiceinnormalcontrolgroupandmodel
control group received intragastric administration of NS per
day after the ﬁrst treatment. The mice in positive control
group were given intragastric administration of 5mg/kg
prednisone (Pre) per day. The mice in MT1 group were
intragastrically treated with 0.01mg/kg melatonin, MT2
0.1mg/kg melatonin, and MT3 1.0mg/kg melatonin. Sera
were collected from the tail vein before treatment (0) and
2, 4, and 8 weeks after treatment to measure the level of
autoantibodies. Twenty-four weeks after pristane adminis-
tration, all mice were killed, and spleens were removed for
immunological detections; meanwhile, nephric tissues were
examined by light microscopy.
2.4. Enzyme-Linked Immunosorbent Assays (ELISAs) for Anti-
ssDNAandHistoneAntibodies. Anti-ssDNAandhistoneIgM
antibodies were detected by an ELISA technique similar to
the one as described in [17]. 96-well ELISA plates coated
with 10mg/L ssDNA or histone antigens were incubated
overnight at 4◦C. On the following day, plates were washed
with PBS-Tween. The plates were incubated with blocking
buﬀer (PBS-2% bovine serum albumin) overnight at 4◦C
and washed with PBS-Tween. After incubated overnight at
4◦C with murine serum diluted to 1:250, the plates were
washed again and then incubated for 2 hours at 4◦Cw i t h
biotin-conjugated-rabbit antimouse IgM antibodies diluted
to 1:200. Subsequently, the plates were washed and incu-
bated for 2 hours at 4◦C with horseradish peroxidase-labeled
avidin in 1:200 dilution. The plates were then washed again,
and 100μLo fs u b s t r a t e[ 3 ,3
 ,5 ,5
 ]—tetramethylbenzidine
(TMB) and hydrogen peroxide solution were added to the
wells for 30 minutes at 37◦C. The reaction was terminated
by addition of 50μLo f2MH 2SO4 per well. The intensity of
the yellow color was read at 490nm in a microplate reader.
The sera of other eight normal BALB/c mice were collected
and detected at the same time, and the mean density and SD
werecalculatedtoserveascontrol.Themeanenzymeindexes
(EI) of the samples in diﬀerent groups were calculated
as:
EI =
intensity of the sample
mean intensity of control mice + 3SD
×100. (1)
2.5. Spleen Cell Culture and Induction of Cytokine. Spleen
cell Culture and induction of cytokines were modiﬁcations
of the methods as described in [18, 19]. Brieﬂy, single-
cell suspensions were prepared from spleens aseptically
removed from mice and cultured in 24-well culture plates
at a ﬁnal concentration of 1 × 106 cells/ml. The cells were
cultured in RPMI-1640 supplemented with 10% fetal calf
serum, 2mM glutamine, 1mM sodium pyruvate, 50μM
2-mercaptoethanol, and 10ml penicillin, streptomycin and
antimycotic solution/L (Sigma). Cultures were stimulated
with 3mg/L ConA, 12mg/L LPS, or medium alone and
incubated at 37◦C in humidiﬁed air with 5% CO2.T h e
supernatant was harvested at 48h and preserved at −20◦C
for cytokine assays.
2.6. Cytokine Assays. The concentrations of interleukin-2
(IL-2),interleukin-6(IL-6),andinterleukin-13(IL-13)inthe
supernatant were determined using appropriate commercial
ELISAs for the murine form of these cytokines. The intensity
of each sample was read at 450nm in a microplate spec-
trophotometer.
2.7. Histopathological Techniques. The kidneys collected
while sacriﬁcing mice were ﬁxed for 24 hours in neutral
buﬀered formalin prior to paraﬃn embedding. Sections
were stained with Haematoxylin and Eosin and Jones silver
methenamine and then examined under a light microscope
for the severity of the renal lesion. Glomerulonephritis, renal
tubular lesions and interstitial inﬂammation were observed,
andthedegreeofseverityofhistologicallesionscharacteristic
of lupus nephritis was evaluated as absent (−), mild (+),
moderate (++), and severe (+++).Mediators of Inﬂammation 3
2.8. Statistical Analysis. Results were expressed as the
mean ±SD. Statistical analysis was performed using Stu-
dent’s two-way t-test with P<. 05 as the minimal level of
signiﬁcance
3. Results
3.1. Eﬀects of Melatonin on Levels of IgM Anti-ssDNA and
Histone Antibodies in Sera. The levels of IgM anti-ssDNA
and histone antibodies were signiﬁcantly diﬀerent between
pristane-injection and melatonin treatment groups (P<. 05,
Figures 1(a) and 1(b)).
Two weeks after a single intraperitoneal injection of
pristane, the level of anti-ssDNA IgM antibodies in sera
begantoincreaseobviously,reachedpeakat4wk,thenbegan
to decrease, and ﬁnally returned to normal at 8wk. In MT1
group, the level of anti-ssDNA IgM antibodies in sera also
increased and reached peak at 4wk, but then decreased more
obviously compared to the model control group (P<. 05).
In MT2 group, the level of anti-ssDNA IgM antibodies in
sera increased during the ﬁrst four weeks, but much lower
than that of model group (P<. 05), and remained normal
in other periods. In MT3 group, the level of anti-ssDNA IgM
antibodies did not increase (Figure 1(a)).
Antihistone antibodies in sera increased 1wk after injec-
tion, reached peak at 4wk, then decreased gradually, and
returned to normal at 8wk. In MT1 group, the levels of
Antihistone antibodies in the sera were signiﬁcantly lower
than that of the model control group (P<. 01) and were
back to normal at 4wk. In MT2 and MT3 groups, the levels
of antibodies increased during the ﬁrst four weeks, but much
lower than model group (P<. 01), and remained normal in
the other periods (Figure 1(b)).
3.2. Eﬀects of Melatonin on Cytokines Production. To gain a
better insight into the inﬂuence of melatonin on cytokines
in SLE, production of Th1-type and Th2-type cytokines by
splenocytesstimulatedwithConAorLPSwasassayedduring
the course of the murine lupus. The results showed that the
production of IL-2, IL-6, and IL-13 changed in pristane-
induced SLE mice (Figure 2). IL-2 production of splenocytes
from mice in model control group was lower than that from
normal mice (P<. 05), while IL-6 and IL-13 production of
splenocytes from mice in model control group was higher
than that from normal mice (P<. 01). In MT2 and MT3
groups, IL-2 levels were up to the normal level and higher
than that of model mice obviously (P<. 05), while the IL-
6 and IL-13 levels were lower than that of the model mice
obviously (P<. 05, .01) (Figure 2).
3.3. Eﬀects of Melatonin on Renal Histopathological Changes.
The renal histopathological changes of the mice are shown in
Table 1 and Figure 3.
As shown in Figure 3(a), renal abnormalities were not
seen in normal mice. The volume and the cell numbers
of glomeruli were normal. Glomerular capillary wall was













































Figure 1: The sera of mice in each group were collected before
treatment (0), 2, 4, and 8 weeks later, and levels of IgM anti-
ssDNA and Antihistone antibodies were detected by ELISA. EI was
calculatedaccordingtotheformula.(a)thelevelofIgManti-ssDNA
antibody in each group, (b) the level of IgM Antihistone antibody
in each group. Data were given in mean ± SD (n = 6–8).
∗P <. 05,
∗∗P <. 01 versus sera at 0wk,  P<. 05, P<. 01 versus sera in
model control mice.
inﬁltration and proliferation of ﬁbroblasts were not seen in
renal interstitial.
As shown in Figures 3(b) and 3(c) and Table 1,m o s t
pristane-injected mice revealed renal abnormalities ranging
from mild to severe patterns. Some glomeruli showed
glomerular atrophy with capillaries dilation and thickening
of capillary walls. Some cites revealed thrombus formation.4 Mediators of Inﬂammation
Table 1: Renal histopathological features of the mice in diﬀerent groups (n = 6–8). The degree of severity of histological lesions was
evaluated as absent (−), mild (+), moderate (++), and severe (+++).
Group














Normal −−−−−− − −
Model ++ ++ ++/+++ ++ ++/+++ ++ ++/+++ ++
Pre + + + +/++ +/++ −∼++ + −
MT1 ++ ++ ++ ++ ++ + ++ ++
MT2 ++ + + + + −∼++ + −































































Figure 2: All mice were sacriﬁced at the end of 24 weeks, and splenic lymphocytes were seeded at 1 × 106 cells/well. IL-2 concentrations in
splenic lymphocytes were stimulated for 48h with 3mg/L ConA. IL-6, and IL-13 concentrations in splenic lymphocytes were stimulated for
4 8hw i t h1 2m g / LL P S .I L - 2 ,I L - 6 ,a n dI L - 1 3c o n c e n t r a t i o n si nc u l t u r es u p e r n a t a n t sw e r ed e t e c t e db yE L I S A .D a t aw e r eg i v e ni nm e a n ±SD
(n = 4–5).
∗∗P <. 01,
∗P <. 05 versus Normal control group,  P<. 05,  P<. 01 versus Model control group.
Mesangial broadening and cell layers increasing were also
observed. Glomerular capsule wall was thick, and the space
between capsule wall and endothelial cells disappeared in
severely aﬀected glomerulus. Some renal tubules showed
dilation and the epithelial cells proliferation. Protein casts
were seen in tubule. An inﬁltration of inﬂammatory cells
such as monocytes, lymphocytes, and plasmacytes with focal
aggregation was seen in renal interstitial. Proliferations of
interstitial ﬁbroblasts were also observed.
T h e r ew e r es o m ei m p r o v e m e n t so fd i ﬀerent degrees in
melatonin-treated mice (Figure 3(d) and Table 1). Glomeru-
lar atrophy and thickening of capillary walls were changed toMediators of Inﬂammation 5
(a) (b)
(c) (d)
Figure 3: The kidneys collected at the time of sacriﬁce were stained with H&E for histological examination. (a) Normal control group
(HE ×200). (b) Model control group (HE × 200). (c) Model control group (HE ×400). (d) MT group (HE ×200).
a mild or moderate degree. Mesangial broadening was also
improved. The space between capsule wall and endothelial
cells was smaller than that of normal mice but there was
an improvement compared to the nontreated model group.
Slight lymphocytes inﬁltration was also observed. Some
renal tubules showed mild dilation and a few protein casts.
Nevertheless, all the changes were less severe than that in
model mice.
4. Discussion
In this study, the immune disturbances of pristane-primed
mice and the eﬀects of melatonin were observed. Since
anti-DNA and histone antibodies were sensitive in SLE [20,
21], we investigated the changes of IgM anti-ssDNA and
Antihistone antibodies and found high levels of autoan-
tibodies in the pristane-injected mice. Renal lesions were
also found in the mice. These results were consistent
with the previous reports. We also found that melatonin
antagonized the increasing levels of IgM anti-ssDNA and
histone autoantibodies, and melatonin could lessen the renal
lesions caused by pristane. Pristane is a peritoneal irritant. It
is well known that IgM class are produced by the B1 (CD5+)
B-cell subset [22], and the B1 subset is highly enriched in
the peritoneal cavity and is expanded in BALB/c mice [23],
raising the possibility that IgM anti-ssDNA and Antihistone
antibodies induced by i.p. pristane are derived from the
subset [24]. Previous studies reported that melatonin had
eﬀects on the ﬁrst antibody immune response (IgM, IgG)
[25]. Some studies indicated that melatonin had two-
way modulation on lymphocytes [26]. So we thought that
melatonin could improve the SLE symptoms by modulating
the overproduction of B cells.
Cytokines network plays an important role in the
developmentofSLE.Insomeinvitroexperiments,melatonin
could inhibit the immune eﬀects of some cytokines and T
lymphocytes [27]. So we observed the eﬀects of melatonin
on the disturbance of cytokines network. IL-6 is thought
as an inﬂammatory cytokine which is secreted by a variety
of tissue cells, including macrophages and Th2-cells. IL-6
level has positive correlation to the activity index of SLE.
Our results showed that the level of IL-6 was increased after
pristane injection, while melatonin could decrease the IL-6
production. The increasing level of IL-6 could cause B cells
to secret more antibodies and promote the development of
nephritis [28]. So the downregulation of IL-6 production by
melatonin is helpful in inhibiting the antibodies production
and renal lesions.
IL-2 is secreted by Th1-cells, and IL-13 is secreted
by Th2-cells. There are some contradictory results in the
documents about the changes of IL-2 and IL-13. So in this
pristane-induced SLE model, we investigated the levels of
the two cytokines. Our results revealed that the level of IL-2
in the pristane-injected mice was lower than that in the
normal mice, while the level of IL-13 in the pristane-injected
mice was higher than that in the normal mice. We also
found that melatonin could decrease the IL-13 production
but increased the IL-2 production. Many reports showed
that the level of IL-2 decreased in the SLE, especially in
the active stage, and that IL-2 could down-regulate the B
lymphocytes activation [29]. Some researches showed that
melatonin could regulate the level of IL-2/IL-2 receptors6 Mediators of Inﬂammation
[30], which may be the mechanism of the inhibitory action
of melatonin on IL-2 production. IL-13, one of the most
important cytokines in the lupus, was believed to be a B-cell
activating factor which resulted in the excessive production
of many autoantibodies [31, 32]. IL-13 has relation to the
renal lesions of SLE [33]. So the downregulation of IL-13
production by melatonin is also helpful in inhibiting the
antibodies production and renal lesions.
The decreasing level of Th1-type cytokine and the
increasing levels of Th2-type cytokine also indicated that
there was a shift from Th1 towards Th2 in pristine-induced
lupus. Some reports showed exogenous melatonin could
activate the CD+
4 T cells and signiﬁcantly promote the Th1-
type cytokines, which participate in regulating the immune
disturbances [34]. Our results showed that melatonin could
upregulate the Th1-type cytokines and downregulate the
Th2-type cytokines. And that indicated melatonin could
modulate the disturbance of cytokine network in the SLE
mice by regulating the imbalance of Th1/Th2.
Prednisone, which is a common drug for SLE [35], was
served as the positive drug in this study. We found that
prednisone had a regulatory eﬀect on pristane-induced SLE.
Compared to prednisone, melatonin had a similar or a little
prior eﬀect on the SLE symptoms. As we have known,
the adverse reactions of prednisone are more common and
serious than melatonin. Thus we thought melatonin may be
a potential drug for SLE.
In conclusion, pristane-induced lupus displays distur-
bance in immune systems, such as high level of autoantibod-
ies and imbalance of cytokine network, which induces the
followed nephritis. The changes are similar to the human
lupus, and pristane is common in the environment; thus
this model is appropriate to study the eﬀects of melatonin
on environmental-related SLE. On the other hand, we also
demonstratedthattheadministrationofmelatonininhibited
the changes in the pristane-induced lupus. And that sug-
gested melatonin had a beneﬁcial eﬀect on environmental-
related lupus. The mechanisms might involve its modu-
lation of disturbances in the immune system, especially
in cytokines network. However, further studies should be
necessary for a better understanding of the regulating
process and the key factor for its action on autoimmune
diseases.
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